All filters
Slidesets
HIV Prevention 2.0- Charles Boucher, MD, PhD
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Eficacia y seguridad de dolutegravir más rilpivirina en la vida real. Resultados a 24 semanas. Estudio DORIVIR- J. Santos
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Dolutegravir and lamivudine as dual maintenance therapy- R. Montejano
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Reasons for discontinuation of dual therapy with dolutegravir and riplivirine- R. Montejano
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Dolutegravir (DTG) based antiretroviral therapy (ART) discontinuation in clinical practice- V. Moreno-Torres
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Experiencia con Inhibidores de la Integrasa en un hospital terciario- I. Mur
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
(Abstract) Predicting Antiviral Drug Toxicity Using Contractility Analysis Of Human IPSC Derived Cardiomyocytes | Brian D. Herman
Presented at:
HIV DART and Emerging Viruses 2016
Slidesets
State of the Art Lecture: What Do We Really Know About Dengue Viruses | Oscar Perng, PhD
Presented at:
HIV DART and Emerging Viruses 2016
Slidesets
Global Burden and Novel Treatment of Noroviruses | Ladislau Kovari, PhD
Presented at:
HIV DART and Emerging Viruses 2016
Slidesets
Zika Neuropathies Beyond Microcephaly | Maurício Lacerda Nogueira, MD, PhD
Presented at:
HIV DART and Emerging Viruses 2016
Slidesets
HIV Knowledge and Hope in Africa | Carol A. Harris, MD
Presented at:
HIV DART and Emerging Viruses 2016
Slidesets
Rapid Zika Detection for Resource-Limited Regions | Mark Sharkey, PhD
Presented at:
HIV DART and Emerging Viruses 2016
Slidesets
(Abstract) In Silico Approaches Towards Broadly Active Flavivirus Protease Inhibitors | Bryan D. Cox
Presented at:
HIV DART and Emerging Viruses 2016
Slidesets
HIV-1 Macrophage Reservoirs: Lessons from Host Macrophage Specific Restriction Factor, SAMHD1 | Baek Kim, PhD
Presented at:
HIV DART and Emerging Viruses 2016
Slidesets
David Barry DART Achievement Award Lecture: The Discovery of SIV and Development of Monkey Models for the Study of HIV/ AIDS | Ronald Desrosiers, PhD
Presented at:
HIV DART and Emerging Viruses 2016
Slidesets
(Abstract) Differential responses of memory CD4+ T cell subsets to HIV latency reversing agents | D. Kulpa
Presented at:
HIV DART and Emerging Viruses 2016
Slidesets
(Abstract) HIV-1 dynamics under integrase inhibitor therapy suggests a subset of cells with slow integration | R.M. Ribeiro
Presented at:
HIV DART and Emerging Viruses 2016
Slidesets
Impact of Jak Inhibitors on HIV Reservoir Maintenance, Lifespan and Expansion in Primary T Cells and Macrophages | Christina Gavegnano, PhD
Presented at:
HIV DART and Emerging Viruses 2016
Slidesets
Current Clinical Therapies for HIV Remission | David Margolis, MD
Presented at:
HIV DART and Emerging Viruses 2016
Slidesets
(Abstract) Anti–HIV drug candidate abx464 prevents intestinal inflammation by producing IL22 in activated macrophages | J. Tazi
Presented at:
HIV DART and Emerging Viruses 2016
Slidesets
Gertrude Elion Distinguished Lecturer Award Lecture Stories on Scientific Discoveries that Transformed HIV into a Manageable Disease | Mark Wainberg, MD
Presented at:
HIV DART and Emerging Viruses 2016
Slidesets
(Abstract) Development of a protease inhibitor-based single-tablet complete HIV-1 regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (DCFTAF) | B. Baugh
Presented at:
HIV DART and Emerging Viruses 2016
Slidesets
(Abstract) Antiviral Activity of tenofovir alafenamide against HIV-1 with thymidine analog mutation(s) and M184V | C. Callebaut
Presented at:
HIV DART and Emerging Viruses 2016